PDCD1 and prostate cancer: Recently, however, Sharma et al. treated prostate cancer patients with anti-CTLA-4 (ipilimumab) and observed both elevated levels of T-cells in tumors and increased expression of PD-1 and VISTA inhibitory checkpoints.